Article Versions Notes

Laffont-Lozes P, Laureillard D, Loubet P, Stephan R, Chiaruzzi M, Clemmer E, Martin A, Roger C, Muller L, Claret P-G, et al. Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France. Antibiotics. 2023; 12(1):88. https://doi.org/10.3390/antibiotics12010088

Laffont-Lozes, Paul, Didier Laureillard, Paul Loubet, Robin Stephan, Myriam Chiaruzzi, Edouard Clemmer, Aurelie Martin, Claire Roger, Laurent Muller, Pierre-Géraud Claret, and et al. 2023. "Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France" Antibiotics 12, no. 1: 88. https://doi.org/10.3390/antibiotics12010088

Laffont-Lozes, P., Laureillard, D., Loubet, P., Stephan, R., Chiaruzzi, M., Clemmer, E., Martin, A., Roger, C., Muller, L., Claret, P.-G., Goulabchand, R., Roux, C., Lavigne, J.-P., Sotto, A., & Larcher, R. (2023). Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France. Antibiotics, 12(1), 88. https://doi.org/10.3390/antibiotics12010088